BMC Medical Co. Ltd.

BMC Medical Co. Ltd.

SSZSE:301367
39.77
CNY
-0.08
(-0.20%)
1.92EPS
24.98P/E
5.84BMarket Cap
Apr 01Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
23.11
31.38
45.48
5.96
7.05
14.26
8.95
6.75
9.32
11.59
Basic EPS, GAAP
1.06
4.14
6.84
2.42
1.55
3.83
2.37
1.24
1.81
1.87
Free Cash Flow per Basic Share
4.3
2.94
5.5
2.68
1
3.54
1.01
1.11
0.79
- -
Dividend per Share
0.11
0.11
0.11
0.13
0.31
- -
1.02
0.53
0.34
0.49
Book Value per Share
15.64
13.18
26.18
3.98
5.22
20.81
22.16
22.55
24.16
24.89
Tangible Book Value per Share
13.56
12.41
25.62
3.94
5.2
20.74
22.11
22.5
23.89
24.64
Basic Weighted Avg Shares
6
6
6
94
94
99
125
125
124
124
Sales/Revenue/Turnover
142
189
258
560
663
1,415
1,122
843
1,159
1,438
Operating Margin (%)
5.26
14.79
16.77
100
23.68
28.84
25.71
14.47
20.84
21.42
Depreciation Expense
3
4
3
2
9
9
19
22
22
- -
Net Income, GAAP
7
25
39
228
146
380
297
155
226
232
Effective Tax Rate (%)
- -
13.88
11.23
14.01
11.1
12.42
10.24
9.96
11.52
13.93
Profit Margin (%)
4.59
13.2
15.04
40.65
21.99
26.87
26.49
18.42
19.46
16.1
Working Capital
67
54
136
350
461
2,560
2,679
2,557
2,722
2,743
LT Debt
- -
- -
- -
6
3
17
16
8
3
11
Total Equity
96
75
155
374
491
2,617
2,787
2,838
3,044
3,133
Return on Invested Capital (%)
- -
26.85
35.55
88.78
33.43
24.16
11.07
5.31
7.27
- -
Return on Capital (%)
- -
27.33
33.83
84.96
33.33
24.25
10.86
5.11
7.05
- -
Return on Common Equity (%)
- -
29.24
33.85
86.16
33.66
24.53
11.03
5.54
7.7
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
42
186
543
LT Borrowings
- -
- -
- -
LT Finance Leases
7
7
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
125
125
125
Market Capitalization
6,038
4,843
5,843

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,000
3,192
3,477
Cash, Cash Equivalents & STI
2,528
2,623
2,904
Accounts Receivable, Net
246
248
224
Inventories
135
209
217
Total Current Liabilities
278
508
734
Payables & Accruals
- -
- -
- -
ST Debt
42
186
543
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
95.9%
7.26%
Free Cash Flow
- -
25.13%
-29.11%
Net Income, GAAP
- -
20.13%
45.23%
Sales/Revenue/Turnover
- -
24.75%
37.46%
Total Cash Common Dividend
- -
- -
-36.26%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
192
190
220
241
843
2025
265
279
- -
351
1,159
2026
309
454
324
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.4
0.34
0.26
0.24
1.24
2025
0.58
0.48
- -
0.37
1.81
2026
0.31
0.71
0.48
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.03
- -
0.53
2025
0.01
0.32
- -
0.01
0.34
2026
- -
0.48
- -
- -
- -

Company Description

CEO
Zhi Zhuang
Full Time Employees
1,161
Sector
Health technology
Industry
Medical specialties
Address
Beijing China
IPO Date
Nov 1, 2022
Business
BMC Medical Co., Ltd. is a medical technology company that develops, manufactures, and commercializes medical devices, consumables, and digital health software for the diagnosis, treatment, and chronic management of sleep-disordered breathing and chronic respiratory diseases. Founded in 2001 and headquartered in Beijing, China, the company is publicly listed on the ChiNext board of the Shenzhen Stock Exchange under the ticker 301367. The company operates globally, supplying products and services to hospitals, sleep disorder centers, clinics, home medical equipment distributors, and individual patients in more than 100 countries and regions across North America, Europe, the Asia-Pacific, Latin America, and the Middle East. The company's core business is organized into several comprehensive product and service categories: non-invasive ventilation devices, comprising continuous positive airway pressure (CPAP), auto-adjusting positive airway pressure (APAP), and bi-level positive airway pressure (BPAP) therapy devices marketed under the RESmart, G3, Luna, and M1 Mini series for the treatment of obstructive sleep apnea and chronic respiratory insufficiency; patient interfaces and consumables, comprising full-face masks, nasal masks, nasal pillows masks, and pediatric interfaces under the iVolve and N5/F5/P2 product series, as well as heated humidifiers, breathing circuits, replacement tubing, and air filters; respiratory therapy equipment, comprising high-flow nasal cannula (HFNC) oxygen therapy systems and stationary and portable medical oxygen concentrators for chronic obstructive pulmonary disease (COPD) management and acute institutional respiratory care; sleep diagnostic systems, comprising clinical multi-channel polysomnography (PSG) devices and portable sleep screening monitors under the PolyWatch series; and digital health and patient management solutions, comprising the proprietary PAP Link cloud-based platform available across web, desktop, and mobile applications for remote therapy data transmission, compliance monitoring, and clinical workflow management. BMC Medical conducts its research, manufacturing, and supply chain operations through multiple specialized subsidiaries and operational centers, including major production and R&D facilities located in Beijing, Tianjin, and Dongguan. In recent corporate developments, the company enacted a strategic corporate restructuring and rebranding initiative, updating its Chinese corporate name to Beijing Remeite Medical Technology Co., Ltd. to align its corporate identity with its primary Remeite brand while maintaining BMC Medical Co., Ltd. as its global corporate name and 301367 as its exchange ticker. The company has also expanded its manufacturing scale and automated production lines across its Dongguan facility, accelerated the international rollout of its next-generation G3 smart ventilator series, and expanded its PAP Link ecosystem with upgraded tele-monitoring and cloud analytics capabilities. Furthermore, BMC Medical has reinforced its overseas distribution partnerships and regulatory clearance portfolio across North American and European healthcare markets following channel stabilization and inventory normalization in global home-care equipment channels.